This one is humming along nicely. It's still interim data and a...

This one is humming along nicely. It's still interim data and a report to market to 'watch this space'.

Good indications that a larger cohort at full recruitment on the higher dose will re-rate this as they come off study at the back end of the year.

Pretty cool this achievement is not arising from a tailored and expensive immunotherapy pairing but apparently some other response driven by Idronoxil-C, that is impacting distal tumours away from the radio-challenged tumour.

Wondering if other programs will be reported on next week... what did you make of this and the upcoming prezzo @RBx ?